Thomas Jefferson University

Jefferson Digital Commons
Department of Pathology, Anatomy, and Cell
Biology Faculty Papers

Department of Pathology, Anatomy, and Cell
Biology

9-23-2019

Conceptualization of a Parasympathetic Endocrine System.
Jonathan Gorky
Thomas Jefferson University

James Schwaber
Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/pacbfp
Part of the Anatomy Commons, and the Pathology Commons

Let us know how access to this document benefits you
Recommended Citation
Gorky, Jonathan and Schwaber, James, "Conceptualization of a Parasympathetic Endocrine
System." (2019). Department of Pathology, Anatomy, and Cell Biology Faculty Papers. Paper
284.
https://jdc.jefferson.edu/pacbfp/284
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Pathology, Anatomy, and Cell Biology Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

HYPOTHESIS AND THEORY
published: 23 September 2019
doi: 10.3389/fnins.2019.01008

Conceptualization of a
Parasympathetic Endocrine System
Jonathan Gorky* and James Schwaber
Daniel Baugh Institute for Functional Genomics and Computational Biology, Thomas Jefferson University, Philadelphia, PA,
United States

Edited by:
Lee E. Eiden,
National Institutes of Health (NIH),
United States
Reviewed by:
Limei Zhang,
National Autonomous University
of Mexico, Mexico
Sarah Haas Lockie,
Monash University, Australia
Vito Salvador Hernandez,
National Autonomous University
of Mexico, Mexico
*Correspondence:
Jonathan Gorky
jonathan.gorky@jefferson.edu
Specialty section:
This article was submitted to
Neuroendocrine Science,
a section of the journal
Frontiers in Neuroscience
Received: 09 March 2019
Accepted: 05 September 2019
Published: 23 September 2019
Citation:
Gorky J and Schwaber J (2019)
Conceptualization of a
Parasympathetic Endocrine System.
Front. Neurosci. 13:1008.
doi: 10.3389/fnins.2019.01008

We here propose a parasympathetic endocrine system (PES) comprised of circulating
peptides released from secretory cells in the gut, significantly modulated by
vagal projections from the dorsal motor nucleus of the vagus (DMV). While most
of these gut peptides mediate well-described satiety and digestive effects that
increase parasympathetic control of digestion (Lee et al., 1994; Gutzwiller et al., 1999;
Klok et al., 2007), they also have actions that are far-reaching and increase
parasympathetic signaling broadly throughout the body. The actions beyond satiety that
peptides like somatostatin, cholecystokinin, glucagon-like peptide 1, and vasoactive
intestinal peptide have been well-examined, but not in a systematic way. Consideration
has been given to the idea that these and other gut-derived peptides are part of an
endocrine system has been partially considered (Rehfeld, 2012; Drucker, 2016), but
that it is coordinated through parasympathetic control and may act to increase the
actions of parasympathetic projections has not been formalized before. Here only gutderived hormones are included although there are potentially other parasympathetically
mediated factors released from other sites like lung and liver (Drucker, 2016). The case
for the existence of the PES with the DMV as its integrative controller will be made
through examination of an anatomical substrate and evidence of physiological control
mechanisms as well as direct examples of PES antagonism of sympathetic signaling in
mammals, including humans. The implications for this conceptual understanding of a
PES reframe diseases like metabolic syndrome and may help underscore the role of the
autonomic nervous system in the associated symptoms.
Keywords: parasympathetic, autonomic, endocrine, gut, vagus

THE DMV AS THE PES CONTROLLER
Although there is evidence that more may participate, four effectors will be considered in this
conceptualization: somatostatin (SST), cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1),
and vasoactive intestinal peptide (VIP). The system as hypothesized is shown in Figure 1 with
annotations as to each aspect of the connectivity. While all four are used as neurotransmitters
and do not readily cross the blood brain barrier (Banks and Kastin, 1985), their presence in the
circulatory system is able to mediate brain function through receptors in the hypothalamus and
area postrema (van der Kooy, 1984; Shaffer and Moody, 1986; Breder et al., 1992; Yamamoto et al.,
2003; Arora and Anubhuti, 2006), both of which prominently project to the dorsal motor nucleus
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fluid retention and Na+ reuptake in kidney, urinary bladder
relaxation, and activation of sweat glands, and is generally
proinflammatory (Grebe et al., 2010; Kreibig, 2010). While not
antagonistic to sympathetic activity, several PES peptides have the
parasympathetic-like activity of enhancing erection induction,
as will be discussed. What follows is evidence for sympathetic
balancing in mammals from each of the PES effectors under
consideration with these effects being summarized in Figure 2.

of the vagus (DMV) (Gray and Magnuson, 1987; Hyde et al.,
1996; Zheng et al., 2005). This sets up a pathway by which DMV
sensing for circulating peptide levels and their effects may be
monitored and controlled. The DMV is capable of modulating
secretion of each of these through direct and indirect means
utilizing gut postganglionic and myenteric plexus neurons. The
work on such vagal influence has not been fully investigated
in any one species, so the literature cited here includes work
done in rats, guinea pigs, dogs, and humans. VIP is secreted
by a subset of secretomotor neurons under the influence of
postganglionic parasympathetic neurons directly modulated by
vagal efferents (Bitar et al., 1980; Kirchgessner and Gershon,
1989; Yuan et al., 2005). SST is released from D-cells and is also
under the influence of postganglionic parasympathetic neurons
with vagal efferent projections having a demonstrable influence
(Ahrén et al., 1986; Greenberg, 1993; Chisholm and Greenberg,
2002). CCK and GLP-1 secretion occurs under direct modulation
by enteric neurons, which themselves have their influence from
the postganglionic parasympathetic neurons. There is evidence
that GLP-1 secretion can occur as a direct consequence of vagal
efferent activity (Rocca and Brubaker, 1999). Although no such
linear pathway has been described for CCK release as a result of
vagal efferent activity, there is molecular and anatomical evidence
that an indirect pathway exists. This pathway contains enteric
secretomotor neurons that produce CCK and interactions with
enteric neurons and possibly postganglionic neurons.
The DMV efferent projections are capable of modulating
the release of several peptides in the gut, including the four
enumerated above. Each of these four peptides are released
through a complex network of local (gut sensing) and central
(vagal) mechanisms. It is possible that the release of all gut
peptides, including but not limited to the four discussed
here, results from generic vagal efferent activity [release of
acetylcholine (Ach)]. There is even evidence that changing the
firing frequency can modulate peptide release of DMV efferents,
which itself may be influenced by the transcriptional milieu
of ion channels (Guzman et al., 1979; Nishi et al., 1985).
DMV efferent neurons have the potential to express several
other transmitters and peptides, the effects of which are still
incompletely understood, especially with regard to local effects
on signaling of gut projections.

Somatostatin
Somatostatin and neuronostatin, a closely related peptide derived
from the same mRNA transcript, mediate broad sympathetic
antagonism and parasympathetic potentiating effects. In the
heart, SST reduces contractility in an Ach-dependent fashion
(Franco-Cereceda et al., 1987; Yoshikawa et al., 1996) and directly
antagonizes sympathetic adrenergic beta receptors (Murray et al.,
2001). Neurostatin also diminishes contractility and has the net
effect of reducing blood pressure when in circulation (Samson
et al., 2008; Vainio et al., 2012). Central administration of SST
causes apnea (Yamamoto et al., 1988) and local levels in the
lungs result in bronchoconstriction (Barrios et al., 1987). SST
also has broad anti-inflammatory effects (Hofland et al., 1999;
Krantic, 2000; ten Bokum et al., 2000). In penile tissue, SST
potentiates the effects of Ach induction of erection (Hedlund
and Andersson, 1985). Even in the eye, SST alone causes
minor pupillary constriction (Bito et al., 1982). Along with
the effects mentioned above, SST is able to mimic the effects
of parasympathetically mediated ischemic preconditioning in
generating cardioprotection (Wang et al., 2005).

Cholecystokinin
The cardiovascular effects of CCK (Lovick, 2009) include
reduction of heart rate (Kaczyńska and Szereda-Przestaszewska,
2015). CCK is also a vasodilator, acting locally (SánchezFernández et al., 2004) or directly antagonizing neurons in rostral
ventrolateral medulla (RVLM) and caudal ventrolateral medulla
(CVLM) that selectively mediate vasoconstriction (Sartor and
Verberne, 2002, 2006). Systemically administered CCK causes
dyspnea with large enough doses in adults (Bradwejn et al., 1998)
and can even induce panic attack like breathing patterns (Shlik
et al., 1997). In the kidney, CCK decreases Na+ reuptake and
reduces vascular resistance (von Schrenck et al., 2000) along with
decreasing renal inflammation (Miyamoto et al., 2012). It has
more broad anti-inflammatory effects via enhancement of vagal
signaling (Luyer et al., 2005). CCK causes pupillary constriction,
but only in primates and humans (Bill et al., 1990).

ANTAGONISM OF THE SYMPATHETIC
NERVOUS SYSTEM
The proposed parasympathetic endocrine system (PES)
counterbalances the sympathetic nervous system broadly, not
just with regard to digestion and orexigenic behavior. As the
role of the four peptides examined here in digestion and satiety
has been well-described (e.g., Arora and Anubhuti, 2006), we
here focus on the other aspects of their control over visceral
functions as they pertain to sympathetic antagonism. First, it is
helpful to recall what the canonical effects of the sympathetic
nervous system are. Sympathetic activation causes pupillary
dilation, increased rate and contractility in the heart, bronchial
dilation in the lungs, constriction of blood vessels generally,
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Glucagon-Like Peptide 1
In the lungs, GLP-1 stimulates macromolecule secretion,
mimicking the effects of Ach, and increases pulmonary blood
flow (Richter et al., 1993). In the kidney, GLP-1 inhibits Na+
reuptake, thus acting as a diuretic (Okerson and Chilton, 2012)
and also induces diuresis in the bladder through contraction
(Ahrén, 2004). Like SST, GLP-1 also enhances erectile function
via direct binding of receptors in erectile tissue (Giagulli
et al., 2015). GLP-1 has also been shown to mediate a robust
cardioprotective response (Ban, 2010; Basalay et al., 2016).
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FIGURE 1 | Anatomical connectivity of the proposed parasympathetic endocrine system. Each solid arrow represents direct synaptic neuronal connections and
dashed lines represent humoral or indirect influence, but with documented influence. The afferent limb is shown on the left and the efferent limb shown on the right.
The letters in the connectivity map identify examples of literature that supports the existence of the specific connection. A, Dockray (2013); B, Dockray (2012);
C, Sandoval (2008); D, ter Horst et al. (1984); E, Sawchenko (1983); F, Egerod et al. (2012); G, Bitar et al. (1980); H, Greenberg (1993); I, Hayakawa et al. (2006);
J, Yuan et al. (2005); K, Ahrén et al. (1986); L, Kirchgessner and Gershon (1989); M, Rocca and Brubaker (1999); N, Furness (2000); O, Liddle (2000) (∗ permissive in
human); P, Chisholm and Greenberg (2002).

RECONSIDERING METABOLIC
SYNDROME

Vasoactive Intestinal Peptide
Like the other peptides, VIP is a potent vasodilator capable of
decreasing heart rate and conduction velocity (Henning and
Sawmiller, 2001). Interestingly, there are more VIP receptors
in the right ventricle compared with the left, although the
functional implications of this is not well understood (Henning
and Sawmiller, 2001). In the kidney, VIP increases Na+
excretion (Rosa et al., 1985) and can induce erection or vaginal
lubrication (Sjöstrand et al., 1981; Ottesen et al., 1984, 1987;
Hedlund and Andersson, 1985). There are several ways in
which VIP mediates anti-inflammatory effects (Pozo et al., 2000;
Ganea and Delgado, 2002; Delgado et al., 2004): inhibits mast
cell degranulation (Tunçel et al., 2000), decreases lymphocyte
proliferation in Peyer’s patches (Stanisz et al., 1986), induces
Treg and regulatory dendritic cell expansion (Chorny et al.,
2005), and is generally immunosuppressive in aqueous humor
(Taylor et al., 1994). In contrast to the other peptides considered
here, VIP is sympathomimetic in the lungs, antagonizing
bronchoconstriction (Barnes and Dixon, 1984). On the balance,
VIP has parasympathetic-like activity in spite of the respiratory
function described here.

Frontiers in Neuroscience | www.frontiersin.org

There are likely more effectors of the PES than the four peptides
explored above with partial or complete sympathetic antagonism.
What makes this idea more than a collection of peptide functions
is that it is coordinated by DMV projections. Reconsideration
of disease processes in this context as a system may provide
a foundation for new treatment approaches. Autonomic
dysfunction accompanies many metabolic syndromes, including
obesity and type II diabetes. There therefore may be some
aspects of metabolic syndrome that are mediated, or at least
modulated by autonomic functions via this parasympathetic
endocrine system.
The diagnostic criteria for metabolic syndrome includes
a combination of at least three of the following: abdominal
obesity, hypertension, hyperglycemia, increased triglycerides,
and decreased high-density lipoprotein (HDL) cholesterol
(Alberti et al., 2005; Opie, 2007). The four peptides highlighted
in this review each contribute to negating the effects of metabolic
syndrome across these five criteria as shown in Figure 3, the
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FIGURE 2 | Summary of published effects of four selected gut peptides and their effects in augmenting parasympathetic function canonically effected via the vagus
nerve and/or sacral parasympathetic projections.

Boehm, 2003), CCK (Pi-Sunyer et al., 1982; Matson and Ritter,
1999; Neary and Batterham, 2009), or GLP-1 (Näslund et al.,
1999; Day et al., 2009; Astrup et al., 2012). Hypertension can
be ameliorated by all four peptides focused upon here; SST
(Rosenthal et al., 1977; Carretta et al., 1989), CCK (Kagebayashi
et al., 2012), GLP-1 (Wang et al., 2013; Katout et al., 2014),
and VIP (Gao et al., 1994). All four peptides contribute to
lowering fasting plasma glucose through a variety of mechanisms
including stimulation of insulin secretion and inhibition of
glucagon secretion; SST (Gerich et al., 1974, 1975; Wahren, 1976;
Vergès, 2017), CCK (Cheung et al., 2009; Irwin et al., 2015),
GLP-1 (Nauck et al., 1993; Toft-Nielsen et al., 1999; Irwin et al.,
2015), and VIP (Kato et al., 1994). Effects on triglycerides and
HDL cholesterol have less evidence to date, yet it has been
demonstrated that GLP-1 can lower triglycerides (Qin et al., 2005;
Meier et al., 2006) with CCK recently shown to have similar
effects on absorption in a preclinical model (Plaza et al., 2018).
Of the four, only GLP-1 can increase HDL cholesterol, although
it appears to be mediated through a variety of other mechanisms
as opposed to a direct effect on the production and processing of
cholesterol (Ponzani et al., 2016).
Apart from the direct symptoms of metabolic syndrome, there
is a broad sympathetic dominance across multiple organ systems
(Tentolouris et al., 2006, 2008). This includes cardiovascular
problems like resting tachycardia, reduced heart rate variability,
and decreased baroreflex sensitivity (Garruti et al., 2012; Verrotti
et al., 2014). Metabolic syndrome causes erectile dysfunction
with a high incidence of comorbidity (Gündüz et al., 2004; Bal
et al., 2007). Also in metabolic syndrome, there is a markedly
decreased release of multiple gut peptides (Verrotti et al., 2014).

FIGURE 3 | Parasympathetic endocrine effects on multi-organ network
interactions that give rise to metabolic syndrome. Aspects of metabolic
syndrome that are inhibited by the four selected gut peptides as was
summarized in the text of the section “Reconsidering Metabolic Syndrome.”
The relationships between different aspects of metabolic syndrome are
recreated from the work of Eckel et al. (2005).

underlying network being based largely on the work of Eckel et al.
(2005). Abdominal obesity can be reduced/prevented through
circulating SST (Lustig et al., 1999; Boehm and Lustig, 2002;
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level of the DMV where there can be integration of peripheral
and central neuronal inputs and orchestration of multiple gut
endocrine activities. This also enables identification via disease
markers and interventions aimed at treating a network of
factors at the central or peripheral level. The conceptualization
of physiology laid out here goes beyond the boundaries of
traditional medical specialties like gastroenterology, neurology,
or cardiology and instead requires a systems approach to health
and medicine. As the ability to deal with human health in a more
comprehensive and complete way matures in the era of big data,
clinicians must be ready to incorporate the growing complexity
of the body as a system in the design and implementation of
therapeutic intervention.

It is possible that the diminished gut peptide release contributes
to the dysautonomia and sympathetic dominance through
absence of antagonism. This may be due to physical changes
in the gut or perturbations in the sensory mechanisms that
otherwise mediate their release. If this is the case, it might
be possible to replace these peptides and treat the autonomic
symptoms. There is an example of this in a clinical trial showing
that the use of SST analog treats diarrhea and orthostatic
hypotension in patients with diabetes (Dudl et al., 1987). Moving
forward, it may be helpful to assay for circulating peptide levels
and use them either a biomarkers of disease or as indications to
initiate peptide replacement therapy. It is likely that replacing the
milieu of peptides rather than one or the other will be required
for maximal clinical benefit.
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